Eli Lilly unveils shared innovation laboratory in San Francisco

3 Dec 2019

Lilly Gateway Labs will provide biotech companies direct access to Lilly scientists and expertise.

Eli Lilly has unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise.

Eli Lilly unveils shared innovation laboratory in San Francisco

"Lilly is making this investment to help speed the discovery of medicines," said Dan Skovronsky, president of Lilly Research Laboratories and chief scientific officer, Eli Lilly and Company. "This model will enable scientists to do what they do best, in an environment that fosters scientific breakthrough. We're excited to see how it will impact our ability to deliver new solutions for patients."

Companies who work in Lilly Gateway Labs will have the opportunity to collaborate with Lilly on projects of mutual interest, participate in shared learning forums with Lilly experts and partners, and have the potential for financial investment from Lilly, venture funds, or both.

"Lilly chose the Bay Area as the location for Lilly Gateway Labs for many reasons, including the ability to tap into the hotbed of biotech innovation already based here," said Julie Gilmore, site head and chief operations officer, Lilly Gateway Labs. "We're excited to further extend our California footprint because of the supportive scientific environment which enables all aspects of drug discovery."

With over 65,000 sq. ft of space, Lilly Gateway Labs offers 32 state-of-the-art, flexibly designed private lab modules. Each module includes lab space for six to eight scientists, office space, and work stations. The space was designed with open areas for collaboration, where scientific symposia and programming will be hosted by Lilly for companies at the site as well as the broader Bay Area scientific community.

"Healthcare is the fastest growing sector of California's economy and Lilly Gateway Labs brings exciting opportunities for partnerships and innovation in drug research and development in South San Francisco that will help lead to groundbreaking therapies and improved patient care," said Rob Lapsley, President and CEO, California Business Roundtable. "California's life sciences industry is one of the nation's – and the world's – leading life sciences hubs, and we look forward to their leadership in South San Francisco to grow new companies and jobs into the future."

Read More

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
French regulator agrees to partial resumption of Tellomak trial patient recruitment

French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina

13 Dec 2019

NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment.

Read more 
Sanofi bolsters its immuno-oncology pipeline for $2.5B

Sanofi bolsters its immuno-oncology pipeline for $2.5B

6 Dec 2019

Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.

Read more